Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘oncology retractions’ Category

“Dramatic impact:” Authors misread breast cancer treatment database, retract paper

with one comment

A journal has retracted a 2016 study on the use of radiation by breast cancer patients after the authors misinterpreted what was reported in a national cancer database.

Correcting for the error, according to the retraction notice, had a “dramatic impact on the original article data and conclusions.”

Quyen Chu, a surgeon at Louisiana State University Health Shreveport, told us that the problem appears to stem from a misunderstanding about the US National Cancer Database (NCDB). After the paper was published, the NCDB pointed out to Chu that a key data point had not been reliably or consistently collected during the timeframe relevant to the study. The database’s user’s manual says essentially the same thing; Chu said he and his authors read it, but misunderstood it.

The original Journal of the American College of Surgeons study looked at whether a 2004 National Comprehensive Cancer Network treatment guideline — which suggested some patients could avoid radiation on top of surgery and hormone therapy — led to an actual decrease in radiation therapy. But the error forced the authors to drop tens of thousands of patients treated before 2004, which had a severe impact on their ability to draw conclusions.

Chu told us:

Read the rest of this entry »

Written by Andrew P. Han

May 11th, 2017 at 11:30 am

Star pediatric oncologist committed misconduct, ethical violations: reports

with 4 comments

Stefaan Van Gool

A high-profile pediatric oncologist quietly left his former institution in 2015 after it concluded his clinical trials had been affected by significant “administrative problems.” But now the results of the university’s investigations and what followed have become public, after a paper in Belgium published a series of news reports last month.

We’re still hazy on some details of the case. The recent news reports allege that Van Gool started some clinical trials without proper ethical approvals and informed consent, and may have misled patients and their families about the benefits and potential side effects of his experimental treatment. Meanwhile, the CEO University Hospitals Leuven (UZLeuven) told us that Stefaan Van Gool, who had appointments at both the hospital and the university (KULeuven), left the hospital in 2015 as a result of administrative problems, but did not disclose the specific nature of these issues.

For the past 15 years or so, Van Gool has been developing and studying a vaccine to treat various cancers, initially at UZLeuven and, after September 2015, at a private clinic in Germany. Today, patients travel to his private clinic from all over the world and pay tens of thousands of dollars to receive the vaccine. But according to Flemish daily newspaper De Standaard, several years ago, UZLeuven began investigating his research and patient care practices. The outcome of these investigations was kept private until last month, after De Standaard published its reports.

Marc Decramer, the CEO of UZLeuven, confirmed that Van Gool left the hospital in 2015 and the university in 2016, but did not provide the specific reasons for his exit:

Read the rest of this entry »

Written by Victoria Stern

April 5th, 2017 at 11:30 am

Authors couldn’t find a patient to give consent for case report. Then the patient found the report.

with 6 comments

When a group of authors decided to write up a curious case of a 35-year-old woman with a mysterious mass that took 11 years to be diagnosed, they tried repeatedly to contact the patient for her permission. When they couldn’t reach her, they published the paper anyway, removing any identifiable information.

But the report apparently included enough details for the patient to recognize herself — and when she read the paper, she asked the authors to retract it.

That’s the story according to the publisher of the 2016 case study, which recently retracted it with this notice:

Read the rest of this entry »

Written by Victoria Stern

February 27th, 2017 at 9:30 am

A “plethora of data errors” prompts authors to retract oncology paper

with one comment

Researchers in China have retracted a 2016 cancer imaging paper because they introduced “a plethora of data errors” while preparing the article for submission.

Although the retraction notice provides no details on what these errors are or how exactly they occurred, it does point the finger at the researchers, explaining that the data errors happened as a result of their “negligence.”

Here’s the 2017 retraction notice for “Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphoma,” published November 25, 2016 in Oncotarget: Read the rest of this entry »

Written by Victoria Stern

February 15th, 2017 at 11:30 am

Cancer researcher logs 6 retractions, bringing total to 10

with 24 comments

Anil Jaiswal

A journal has retracted six papers by a cancer researcher at the University of Maryland in Baltimore, bringing his total to 10.

The retractions cite an investigation by the university, and detail problems ranging from duplicated images, to tweaking an image to conceal particular bands, to including unreliable data.

Three of the papers had already been flagged by the journal with expressions of concern. The last author on all the papers is Anil Jaiswal, a professor in the pharmacology department. He has issued four previous retractions.

Bruce Jarrell, the Chief Academic and Research Officer and Senior Vice President at the University of Maryland, told us at least two more retractions are forthcoming:

Read the rest of this entry »

Study of child with rare cancer retracted due to lack of parental consent

with one comment

Researchers in Ireland have retracted a case study about a rare type of cancer in a child because – contrary to what they claimed in the paper – they had not obtained the necessary permission from the parents.

In the June 2016 article, the authors stated they had received “written informed consent” from the parents to publish the case. But according to the retraction notice — issued just a few months later in October — that was not the case.

Here’s the retraction notice for “Paediatric Ewing-like sarcoma arising from the cranium – a unique diagnostic challenge,” which for legal reasons, the publisher has withdrawn from public view:

Read the rest of this entry »

Dangerous chemo mistake retracted by journal after two years

with 3 comments

An oncology journal has retracted a 2014 paper that contained a potentially fatal mistake.

Specifically, the paper suggested that a chemotherapy drug be injected intrathecally — i.e., in the spine. But according to the retraction notice, the medical literature has unequivocally shown that that form of treatment is “uniformly fatal.”

The retraction comes approximately 18 months after the journal published a letter to the editor alerting readers to the risky wording in the 2014 paper.

Here’s the notice, issued by Hematological Oncology:

Read the rest of this entry »

Journal retracts gastric cancer study with multiple duplications, authors MIA

with 3 comments

An oncology journal has decided to retract a 2012 paper on gastric cancer after discovering duplicated data in multiple figures.

According to the retraction notice, the journal’s editorial board received a tip from a reader regarding the potential figure issues. Oncology Reports launched an investigation, which confirmed the allegations. The authors failed to respond to the journal’s multiple requests for more information.

Here’s the retraction notice: Read the rest of this entry »

Oops: Supposedly untreated cancer patients had surgery, after all

with one comment

gmrThe first author of a 2016 paper has retracted it after realizing that all the lung cancer patients that were supposed to have been untreated did, in fact, have surgery to remove their tumors. 

Zhao Kai, the study’s first author from the Qilu Hospital of Shandong University and Zibo Central Hospital (both in China), took full responsibility for the error.

Here’s the retraction notice, published last month in Genetics and Molecular Research: Read the rest of this entry »

Journal pulls cancer paper that used others’ data; authors MIA

without comments

A journal has retracted a paper after a reader pointed out some of the data looked familiar — and the authors never responded to the allegations.

According to the retraction notice in the International Journal of Molecular Medicine, the reader showed the journal that the histological data in two of the figures were from another published paper by different researchers. But when the journal contacted the authors on several occasions, they didn’t hear back. 

Here’s the retraction notice: Read the rest of this entry »

Written by Dalmeet Singh Chawla

December 15th, 2016 at 11:30 am